Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Predictive Oncology ( (POAI) ) has issued an update.
On March 14, 2025, Predictive Oncology entered into an agreement with DeRoyal Industries to sell its Eagan Business, which involved products for automated medical fluid disposal, including the STREAMWAY® product line. This transaction led to the reclassification of the Eagan Business as discontinued operations in the company’s financial statements for 2024 and 2023, reflecting a strategic shift in the company’s focus and potentially impacting its operational and financial landscape.
The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Spark’s Take on POAI Stock
According to Spark, TipRanks’ AI Analyst, POAI is a Underperform.
Predictive Oncology’s overall stock score is negatively impacted by severe financial instability, poor valuation metrics, and ongoing compliance issues with Nasdaq. The bearish technical indicators further suggest weak market sentiment, contributing to a low score.
To see Spark’s full report on POAI stock, click here.
More about Predictive Oncology
Predictive Oncology Inc. operates in the biotechnology industry, focusing on the application of artificial intelligence in oncology drug discovery. The company leverages a proprietary biobank of over 150,000 tumor samples to offer solutions that enhance drug discovery and development, aiming to improve cancer treatment outcomes.
Average Trading Volume: 167,698
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.53M
For detailed information about POAI stock, go to TipRanks’ Stock Analysis page.